Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Kramer

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 9, 2025
Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemicOmbeline Jollivet, Arantxa Urchueguía-Fornes, Kocfa Chung-Delgado, et al.
The Pediatric Infectious Disease Journal|November 26, 2024
Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World StudyEric Jeziorski, Antoine Ouziel, Marie Cotillon, et al.
Infection|February 19, 2025
RSV is the main cause of severe respiratory infections in infants and young children in Germany - data from the prospective, multicenter PAPI study 2021-2023Martin Wetzke, Matthias Lange, Cordula Koerner-Rettberg, et al.
The Lancet. Respiratory Medicine|January 12, 2025
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021-23)Sarah F Hak, Valérie D V Sankatsing, Joanne G Wildenbeest, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|December 19, 2019
Extensively drug-resistant <i>Klebsiella pneumoniae</i> ST307 outbreak, north-eastern Germany, June to October 2019Sebastian Haller, Rolf Kramer, Karsten Becker, et al.
The Journal of Infection|April 7, 2024
Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national studySaverio Caini, Jean-Sebastien Casalegno, Ana Paula Rodrigues, et al.
Human Vaccines & Immunotherapeutics|May 13, 2024
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocolNarmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, et al.
European Journal of Pediatrics|May 2, 2025
Respiratory syncytial virus-related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL studyAngela Manzanares, Jacobo Pardo-Seco, Irene Rivero-Calle, et al.
The Lancet. Infectious Diseases|May 3, 2024
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal studySonia Ares-Gómez, Narmeen Mallah, María-Isolina Santiago-Pérez, et al.
The Lancet. Infectious Diseases|January 15, 2026
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational studyJosefina L Razzini, Iago Giné-Vázquez, Jing Jin, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 9, 2025
Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemicOmbeline Jollivet, Arantxa Urchueguía-Fornes, Kocfa Chung-Delgado, et al.
The Pediatric Infectious Disease Journal|November 26, 2024
Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World StudyEric Jeziorski, Antoine Ouziel, Marie Cotillon, et al.
Infection|February 19, 2025
RSV is the main cause of severe respiratory infections in infants and young children in Germany - data from the prospective, multicenter PAPI study 2021-2023Martin Wetzke, Matthias Lange, Cordula Koerner-Rettberg, et al.
The Lancet. Respiratory Medicine|January 12, 2025
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021-23)Sarah F Hak, Valérie D V Sankatsing, Joanne G Wildenbeest, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|December 19, 2019
Extensively drug-resistant <i>Klebsiella pneumoniae</i> ST307 outbreak, north-eastern Germany, June to October 2019Sebastian Haller, Rolf Kramer, Karsten Becker, et al.
The Journal of Infection|April 7, 2024
Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national studySaverio Caini, Jean-Sebastien Casalegno, Ana Paula Rodrigues, et al.
Human Vaccines & Immunotherapeutics|May 13, 2024
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocolNarmeen Mallah, Sonia Ares-Gómez, Jacobo Pardo-Seco, et al.
European Journal of Pediatrics|May 2, 2025
Respiratory syncytial virus-related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL studyAngela Manzanares, Jacobo Pardo-Seco, Irene Rivero-Calle, et al.
The Lancet. Infectious Diseases|May 3, 2024
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal studySonia Ares-Gómez, Narmeen Mallah, María-Isolina Santiago-Pérez, et al.
The Lancet. Infectious Diseases|January 15, 2026
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational studyJosefina L Razzini, Iago Giné-Vázquez, Jing Jin, et al.
Pageof 4